Case Studies

Corporate Strategy:

Drawing on Deal Experience to Develop Portolio Strategy
A biosimilars developer had five assets in development and needed to determine its investment and portfolio strategy. Proaltus performed a rigorous commercial and competitor landscape analysis and weighed these insights in the context of the deal market.

Working closely with the client’s business and technical teams, Proaltus elucidated a range of investment, financing, and partnering alternatives. Partnering and investment strategy recommendations for different portfolio alternatives included timing and execution considerations on a region by region and asset by asset basis. The recommendations were approved by the board and are being pursued in their entirety.

Pricing and Market Access Strategy:

Including Payer Perspectives to Support Commercial Success
A global pharmaceutical company had in-licensed two anti-infective compounds with outstanding pricing and reimbursement risks. The client wished to understand more clearly the trade-offs between different prices, clinical profiles, and access / reimbursement levels and the resulting revenue impacts.

Working with a cross-functional client team that included US and EU5 representation, Proaltus performed a thorough information gap analysis that included internal stakeholder interviews within the client organization, conducted qualitative interviews with physicians and payers, ran quantitative exercises with physicians and payers, and developed a robust revenue model. Recommendations included optimal pricing and related market access recommendations that considered the level of differentiation each product offered as well as royalty payments.

Deal Preparation:

Innovative Licensing Concepts Deliver Strategic Value
MaxCyte, a cell therapy company, faced two strategic imperatives: generating near-term revenue and deriving value from its academic collaborations. Bringing a fresh perspective, a new path forward was identified: instead of advancing drug candidates through an extended regulatory path, at an earlier clinical stage MaxCyte successfully accelerated the out-licensing of a therapeutic program that had been previously in-licensed from an academic center.

“[Proaltus General Partner] Chris Lehman served as a critical catalyst in our strategic market launch session for a new therapeutic and led the implementation of our business development effort.” – Doug Doerfler, CEO, MaxCyte, Inc.